Inotiv, Inc. (NOTVQ)
| Market Cap | 387.26K -99.4% |
| Revenue (ttm) | 507.36M +5.6% |
| Net Income | -86.97M |
| EPS | -2.53 |
| Shares Out | 34.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 243,786 |
| Open | 0.0111 |
| Previous Close | 0.0150 |
| Day's Range | 0.0111 - 0.0180 |
| 52-Week Range | 0.0070 - 2.4400 |
| Beta | 3.92 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Inotiv
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the ... [Read more]
Financial Performance
In fiscal year 2025, Inotiv's revenue was $513.02 million, an increase of 4.54% compared to the previous year's $490.74 million. Losses were -$68.63 million, -36.72% less than in 2024.
Financial StatementsNews
Inotiv Successfully Completes Financial Restructuring Process
WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and ...
Inotiv Announces Confirmation of Plan of Reorganization
WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and ...
Inotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future Growth
WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and ...
Inotiv Quarterly report: Q2 2026
Inotiv has published its Q2 2026 quarterly earnings report on May 11, 2026.
Inotiv Provides Notice Regarding Cybersecurity Incident
WEST LAFAYETTE, Ind., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical dr...
Inotiv Slides: Investor presentation
Inotiv has posted slides in relation to its latest quarterly earnings report, which was published on February 9, 2026.
Inotiv Earnings Call Transcript: Q1 2026
Q1 2026 delivered strong DSA growth and margin improvement, offset by RMS weakness from lower NHP volumes. Cost reduction and site optimization efforts are underway, with innovation and new collaborations supporting future growth. No formal FY 2026 guidance was provided.
Inotiv Quarterly report: Q1 2026
Inotiv has published its Q1 2026 quarterly earnings report on February 9, 2026.
Inotiv Earnings release: Q1 2026
Inotiv released its Q1 2026 earnings on February 9, 2026, summarizing the period's financial results.
Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update
WEST LAFAYETTE, Ind., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery ...
Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026
WEST LAFAYETTE, Ind., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical dr...
Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery
WEST LAFAYETTE, Ind., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical dr...
Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities
WEST LAFAYETTE, Ind., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization (CRO) specializing in nonclinical and analyti...
Inotiv Earnings Call Transcript: Q4 2025
Q4 and full year 2025 saw strong revenue growth, especially in DSA, with improved margins and reduced losses. Operational efficiencies, site consolidations, and technology upgrades drove cost savings, while a cybersecurity incident had some impact but was managed effectively.
Inotiv Annual report: Q4 2025
Inotiv has published its Q4 2025 annual report on December 3, 2025.
Inotiv Earnings release: Q4 2025
Inotiv released its Q4 2025 earnings on December 3, 2025, summarizing the period's financial results.
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update
– Fourth quarter fiscal 2025 revenue up 5.9% to $138.1 million– Fiscal 2025 revenue increased 4.5% to $513.0 million– Fourth quarter fiscal 2025 operating loss decreased 48.5% to $6.8 million– Fis...
Inotiv Ranked Number 182nd Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™
Building a Unified, Client-Focused, Early Stage CRO Through Strategic Expansion and Service Development Powers 448% Revenue Growth from Fiscal Year 2021 to Fiscal Year 2024 Building a Unified, Client-...
Inotiv, Inc. to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results and Host Conference Call on Wednesday, December 3, 2025
WEST LAFAYETTE, Ind., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical dr...
Inotiv Transcript: Jefferies London Healthcare Conference 2025
Q4 saw strong revenue and DSA award growth, with operational efficiencies from integration and site consolidation. Pricing has firmed, margins are improving, and NHP activity stabilized. Debt restructuring and cyber recovery efforts are ongoing, with systems fully restored.
Inotiv, Inc. Announces Preliminary Fiscal 2025 Fourth Quarter and Full Year Results
Preliminary Expected Fourth Quarter 2025 Revenue of $137.5 to $138.5 Million Preliminary Expected Full Year 2025 Revenue of $512.5 to $513.5 Million
Halper Sadeh LLC Encourages Inotiv, Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Inotiv, Inc. (NASDAQ: NOTV) breached their fiduciary duties to shar...
Inotiv Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Significant growth achieved through integration, operational optimization, and a focus on preclinical CRO services. Recent quarters saw strong DSA award growth and improved financial performance, with a clear path to long-term EBITDA targets. Customer-centric strategies and infrastructure investments underpin future expansion.
Inotiv Slides: H.C. Wainwright 27th Annual Global Investment Conference
Inotiv has posted slides in relation to its latest quarterly earnings report, which was published on September 10, 2025.
Inotiv Transcript: Baird Global Healthcare Conference 2025
Revised summary: Integration of acquisitions and operational improvements have driven strong growth in DSA awards and margins, while RMS remains stable amid market shifts. Capacity supports near-term growth, and recent investments should yield efficiencies. The organization has shown resilience through a cyberattack and adapts to regulatory changes.